Novartis: Cosentyx may modify the course of psoriasis.

(CercleFinance.com) - Novartis today announced new data suggesting that Cosentyx may modify the course of psoriasis, leading to long-term skin clearance.


Following treatment of one year, patients with continuous treatment maintained their high level of response, while 21% of the patients that discontinued treatment maintained skin clearance for up to one year without treatment, the Swiss biopharmaceutical firm said on Tuesday.

Amongst them, 10% managed to maintain skin clearance after two years without treatment.

"These results suggest that Cosentyx may go beyond simply treating symptoms and could actually modify the course of psoriasis," said Vas Narasimhan, Novartis' chief medical officer.

As a reminder, Cosentyx is already approved in over 75 countries for the treatment of moderate-to-severe plaque psoriasis, which includes European Union countries, Japan, Switzerland, Australia, the US and Canada.

Copyright (c) 2017 CercleFinance.com. All rights reserved.